Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant short-course radiotherapy plus chemotherapy and camrelizumab for operable esophageal squamous cell carcinoma
ChiCTR2300068134Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Feb 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Cancer Hospital. Primary endpoints: Pathological complete response rate and R0 resection rate. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300068134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068134.